In this @-week , open-label , multicenter , randomized , noninferiority trial with @ weeks prior insulin optimization , @ patients with insufficient postoptimization glycated hemoglobin A@c ( HbA@c ) were randomized to exenatide ( @-@ g/day ) or thrice-daily mealtime lispro titrated to premeal glucose of @-@ @ mmol/L , both added to insulin glargine ( mean @ units/day at randomization ) and metformin ( mean @,@ mg/day ) .